<img src="https://cdn.it.bgi.com/source/Screen Shot 2022-06-30 at 2.50.32 PM.png" style="max-width:100%;" contenteditable="false"/>From July 26 to 28, BGI will be exhibiting at
the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in
Chicago. With over 700 companies exhibiting, the 2022 AACC Clinical Lab Expo is
a premier global laboratory medicine exposition. BGI is a world-leading genomics and life
science organization. The company provides cutting-edge genomic products and
solutions to advance genetic research, precision medicine and diagnostics
across more than 100 countries.In North America, BGI’s expanding <a target="_blank" href="https://cdn.it.bgi.com/source/BGI-IVD-Portfolio-20220617.pdf">infectious disease IVD product portfolio</a>&nbsp;includes its FDA EUA COVID RT-PCR kit, multiplex PCR testing products (RUO), as
well as its upcoming PMseqTM&nbsp;(Pathogen Microorganism
Sequencing) solution for cascading and comprehensive infectious disease
identification and surveillance for public health and pandemic prevention.BGI offers our <a target="_blank" href="https://www.bgi.com/us/IVD">IVD partners</a> with unique
access to our global manufacturing infrastructure and worldwide distribution
network. BGI is also seeking opportunities to commercialize our own genomic
diagnostic solutions through OEM, co-development and distribution.















At AACC 2022, our Abstract Poster (Number:
A-152; see highlights below) will be displayed in Exhibition Poster Hall. Our
friendly and professional team will be exhibiting at booth #1461. We look
forward to meeting you!<img src="https://cdn.it.bgi.com/source/Poster 2.png" style="max-width:100%;" contenteditable="false"/>More information about the&nbsp;AACC: <a href="https://meeting.aacc.org/" style="font-size: 16px; letter-spacing: 0px; background-color: rgb(255, 255, 255);">AACC 2022 website</a>

Discover more Infectious Disease Diagnostic Solutions with BGI at AACC 2022

<img src="https://cdn.it.bgi.com/source/14d1dd0c4bd58c87451d60284436032.png" alt="14d1dd0c4bd58c87451d60284436032.png" data-href="" style=""/>We are excited to meet you in person at ASHG in Washington DC this year! &nbsp;As a global multi-omics service provider, we are excited to announce the following programs at ASHG this year: Booth Exhibition:Come talk to us at our booth #309 to learn about our multi-omics analysis solution, a unique integration of NGS and mass spectrometry services. We have been the trusted DNBSEQ™ sequencing service provider in US since 2017 to support the genetics research community. Our US-based team allows additional integration of proteomics and metabolomics into a comprehensive portfolio of omics services for the academic and biopharma industries. Lunch Workshop:<img src="https://cdn.it.bgi.com/source/Speaker Graphic-2.png" alt="Speaker Graphic-2.png" data-href="" style="">We’ve had the distinct honor of supporting two incredible researchers in the genomics field. Our two talks “The Additional Impact of Genetic Ancestry over Self-reported Race/Ethnicity to Prevalence of KRAS Mutations and Allele-specific Subtypes in Non-small Cell Lung Cancer” and “Full-Length RNA and RNA Velocity in Single Cells” will highlight the innovative genomic approaches that identify and treat a variety of diseases. Dr. Xin-An Wang from Harvard University specializes in population and molecular environmental health. She will give a talk on the additional impact of genetic ancestry over self-reported race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer (NSCLC). The interplay between self-reported race and/or ethnicity (SIRE) and genetically inferred ancestry (GIA) on KRAS mutations and allele-specific subtypes is largely unknown. Dr. Wang and her team analyzed patients from the Chinese OrigiMed (OM) cohort and Boston Lung Cancer Survival (BLCS) cohort all of whom had well-annotated baseline covariates including age at diagnosis, sex, clinical stage, SIRE, cancer histology and smoking status. Their findings reveal factors that can contribute to more accurate diagnostics and clinical decision-making, ultimately benefiting diverse patient populations of NSCLC. Dr. Tang received his Ph.D. in Biochemistry from the University of Nevada, Reno (UNR). He served as research assistant professor and co-director of Nevada Center of Single Cell Research. Dr. Tang published over 25 articles in highly ranked international scientific journals in the fields of spermatogenesis and novel genome sequencing technologies. He also served as editor for Biology of Reproduction and re-viewers for Nature Communications, PIOS ONE, Cell Communication and Signaling (CCS). Dr. Tang currently serves as R&amp;D director at BGI-Tech Global. Dr. Tang will deliver a talk on “Full-Length RNA and RNA Velocity in Single Cells.” During his presentation, he will introduce the differences between PacBio-based HIT-scISOseq and Nanopore-based FLOUR-seq. He will also discuss why RNA velocity software has become the most popular choice." These two lead scientists will present featured topics in Room 143AB of Walter E. Washington Convention Center from 12:00 PM to 1:00 PM on Saturday, Nov 4th. Lunch will be provided for free! <a href="https://cdn.it.bgi.com/source/us-special-promotion-for-2023-ashg-20-off-20230928.pdf" target="_blank">Special Promotions:</a>We are glad to start offering our special fall promotions at ASHG. Visit BGI booth #309 to receive a 20% discount on our DNBSEQ™ NGS services and additional offers!<img src="https://cdn.it.bgi.com/source/final513.png" alt="final513.png" data-href="" style="">

Join us at ASHG 2023 (Booth #309)

<img src="https://cdn.it.bgi.com/source/bannerimageresized.png" style="max-width:100%;" contenteditable="false"/> The countdown is on and we cannot
wait to see you at AACC 2023!This year, we are thrilled to present SENTIS and
PMseq early access programs. SENTIS™ Cancer+
Discovery Panel offers one of the market’s most
comprehensive and accurate NGS-based testing solution for identifying
actionable mutations in cancer. It covers 688 cancer-related genes and
interrogates the most common types of alterations, including SNVs, indels, CNVs,
and fusions in solid tumors. SENTISTM Hereditary
Cancer Panel focuses on genes associated with a predisposition to cancer. By analyzing germline
mutations in 79 genes&nbsp;associated with&nbsp;24 types of hereditary
cancer,&nbsp;including breast, ovarian, colorectal, prostate, and stomach
cancer, the panel helps identify cancer-causing mutations, guiding treatment
decisions and further testing for at-risk individuals. 













PMseqTM is a powerful high-throughput
sequencing technology that detects and identifies suspected pathogenic
microorganisms in infected specimens. It provides comprehensive reports for rapid
and accurate detection of difficult- and critical-to-detect infections, and
promotes the rational use of antibiotics under Antibiotic Stewardship Programs
(ASP) with insights of antimicrobial resistance and susceptibility (AMR).<table border="0" width="100%" cellpadding="0" cellspacing="0" style="text-align:center;"><tbody><tr><th>Exhibit Location and Hours</th></tr><tr><td>Anaheim Convention
Center, Anaheim, CA.</td></tr><tr><td>July 25th&nbsp;(Tuesday): 9:30 a.m. – 5:00 p.m.</td></tr><tr><td>June 26th&nbsp;(Wednesday): 9:30 a.m. – 5:00 p.m.</td></tr><tr><td>June 27th&nbsp;(Thursday): 9:30 a.m. – 12:00 p.m.</td></tr></tbody></table><table border="0" width="100%" cellpadding="0" cellspacing="0"><tbody><tr><th>Booth Exhibition</th></tr></tbody></table><table><tbody>
 <tr>
 <td>
 <img src="https://cdn.it.bgi.com/source/orso.jpg" style="max-width:100%;" contenteditable="false"/>
 </td>
 <td>
 Visit
 us&nbsp;at&nbsp;booth #915, tell us about your projects, and get to
 know what’s new with BGI and our SENTIS and PMseq early access programs. Not
 to forget, we will be handing out our popular BGI stuffed polar bears and mobile phone stands to our visitors (while supply lasts)!&nbsp;
 </td>
 </tr></tbody></table>

Join BGI at AACC 2023 (Booth #915)

<img src="https://cdn.it.bgi.com/source/insidenewsimage.png" style="max-width:100%;" contenteditable="false"/>The countdown is on and we cannot
wait to see you at ASM 2023!This year, we are thrilled to present PMseqTM,
our pathogen metagenomics sequencing solution. 







PMseqTM is direct high-throughput
sequencing of infected specimens, through microbial-specific database
comparison and intelligent algorithm analysis, obtaining species information of
suspected pathogenic microorganisms, and providing comprehensive and in-depth reports
for rapid and accurate detection of difficult- and critical-to-detect
infections, and promoting the rational use of antibiotics under Antibiotic
Stewardship Programs (ASP) with insights of antimicrobial resistance and
susceptibility (AMR).<table border="0" width="100%" cellpadding="0" cellspacing="0"><tbody><tr><th>Exhibit Location and Hours</th></tr><tr><td>George R. Brown Convention Center, Houston, TX</td></tr><tr><td>June 16th (Friday): 10:00 a.m. - 5:00 p.m.</td></tr><tr><td>June 17th (Saturday): 10:00 a.m. - 5:00 p.m.</td></tr><tr><td>June 18th (Sunday): 10:00 a.m. - 4:00 p.m.</td></tr></tbody></table><table border="0" width="100%" cellpadding="0" cellspacing="0" style="text-align:center;"><tbody><tr><th>Booth Exhibition</th></tr><tr><td> <img src="https://cdn.it.bgi.com/source/orso.png" contenteditable="false" style="font-size: 14px; max-width: 100%;"/> Visit
us&nbsp;at&nbsp;booth #1722, tell us about your projects, and get to
know what’s new with BGI and our PMseqTM early access program. Not to
forget, we will be handing out our popular BGI stuffed polar bears and mobile phone
stands to our visitors (while supply lasts)!&nbsp;</td></tr></tbody></table>

Join BGI at ASM 2023 (Booth 1722)

<img src="https://cdn.it.bgi.com/source/bannerasm.png" style="max-width:100%;" contenteditable="false"/> The countdown is
on and we cannot wait to see you at ASMS 2023! This year, we are thrilled to present a&nbsp;complete line of mass
spectrometry services from our laboratory in San Jose, California, for all your
research and drug development needs. Our state-of-the-art mythology can help
simplify the challenge of proteomic analysis, metabolomics analysis
and biologics characterization. We provide services for biomarker
discovery, drug target deconvolution, mechanism of action (MOA), candidate
ligand screening, and comprehensive characterization of biologics.<img src="https://cdn.it.bgi.com/source/servicesprovided.jpg" style="max-width:100%;" contenteditable="false"/>We look forward
to offering you our special <a href="https://genomics.bgi.com/multiomics-promotion">promotion</a> for:●&nbsp;Proteome +
Transcriptome Correlation Analysis 
●&nbsp;Metabolome + Metagenomic Survey Correlation Analysis 
●&nbsp;Quantitative Proteome + Phosphoproteome Correlation Analysis&nbsp;Don’t forget to meet our
scientists in poster sessions (10:30 am to 2:30 pm) to learn about our novel
research in proteomics and metabolomics:&nbsp;&nbsp;June 5 (Monday)MP 587: Multi-species of Benchmarking
Phospho-DIA Comparison of Commercial Sample Prep KitsPresenter: Billy Newton, BGI Americas,
San Jose, California MP 575: A Bio-Zr Based Enrichment for
the Phosphopeptides from Human and Animal TissuesPresenter: Qidan Li, BGI-Shenzhen, ChinaJune 6 (Tuesday)TP 484: A High-Efficiency Method for Simultaneous
Quantification of Seven Classes of PhytohormonesPresenter: Lingyun Chen, BGI-Shenzhen,
ChinaTP 485: Targeted Metabolic Analysis of Bile
Acids in Biological Samples by Ultra-performance Liquid Chromatography Tandem Mass
Spectrometry







































Presenter: Yun Zhao, BGI-Shenzhen, China

News and Events

Discover more Infectious Disease Diagnostic Solutions with BGI at AACC 2022

Newest News and Events